Related Experiment Video

Updated: Oct 8, 2025

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

53.1K

Newly Invented Micellized Vitamin K2 Recovered Prolonged Prothrombin Time under Obstructive Jaundice in Rats with

Yoshiki Hoshino1, Takaaki Sugihara1, Suguru Ikeda1

  • 1Division of Medicine and Clinical Science, Department of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University.

Journal of Nutritional Science and Vitaminology
|January 4, 2022
PubMed

Insights

New micellized vitamin K2 effectively treats coagulopathy in cholestatic liver disease models. Co-administration with taurocholic acid enhances vitamin K2 absorption and normalizes prothrombin time, even in obstructive jaundice.

Area of Science:

  • Hepatology
  • Gastroenterology
  • Pharmacology

Background:

  • Cholestatic liver diseases cause vitamin K malabsorption, leading to coagulopathy.
  • Vitamin K supplementation is a known preventive measure for this condition.
  • A novel micellized vitamin K2 (m-vitK2) formulation was developed to improve efficacy.

Purpose of the Study:

  • To evaluate the efficacy of m-vitK2 in treating coagulopathy in a rat bile duct ligation (BDL) model.
  • To assess the impact of co-administering taurocholic acid (TA) on m-vitK2 absorption and therapeutic effect.

Main Methods:

  • Rats underwent bile duct ligation (BDL) to induce cholestasis and coagulopathy.
  • Groups received daily oral administration of m-vitK2, or m-vitK2 with TA, for seven days.
  • Absorption was evaluated by comparing m-vitK2 with and without TA in BDL rats.

Main Results:

  • m-vitK2 administration significantly recovered prothrombin time (PT) in BDL rats.
  • Co-administration of m-vitK2 with TA enhanced absorption compared to m-vitK2 alone.
  • m-vitK2 combined with TA completely normalized PT and reduced micelle size, indicating improved absorption.

Conclusions:

  • Micellized vitamin K2 effectively reverses coagulopathy in obstructive jaundice models.
  • Taurocholic acid enhances the absorption of micellized vitamin K2, improving its therapeutic potential.
  • This formulation offers a promising approach for managing vitamin K deficiency in cholestatic liver diseases.
Keywords:
cholestasiscirrhosiscoagulopathyobstructive jaundicevitamin K

More Related Videos

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis04:38

Partial Bile Duct Ligation in the Mouse: A Controlled Model of Localized Obstructive Cholestasis

Published on: March 28, 2018

15.9K
A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice07:48

A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice

Published on: October 13, 2018

7.8K

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.4K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
12
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
9
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
9
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
7